Download PDF
Fortschr Neurol Psychiatr 2001; 69(SH2): 65-74
DOI: 10.1055/s-2001-16533
© Georg Thieme Verlag Stuttgart · New York

Zur klinischen Relevanz der Wirkung von Clozapin auf die Freisetzung von Zytokinen und löslichen Zytokinrezeptoren

On the Clinical Relevance of Clozapine-Triggered Release of Cytokines and Soluble Cytokine-ReceptorsTh. Pollmächer1 , A. Schuld1 , Th. Kraus1 , M. Haack1 , D. Hinze-Selch1,2
  • 1Max Planck Institut für Psychiatrie, München
  • 2Klinik für Psychiatrie und Psychotherapie,Christian Albrechts Universität, Kiel
Further Information

Publication History

Publication Date:
21 August 2001 (online)

Also available at
    Permissions and Reprints

Zusammenfassung:

Zytokine sind zentrale Mediatoren der Interaktion immunkompetenter Zellen, aber auch der Kommunikation des Immunsystems mit anderen physiologischen Systemen einschließlich des ZNS. Untersuchungen der letzten Jahre zeigen, dass das Neuroleptikum Clozapin in vivo die Freisetzung von Zytokinen und löslichen Zytokinrezeptoren stimuliert. Diese Wirkung betrifft insbesondere das Tumor-Nekrose-Faktor(TNF)-System, das Interleukin(IL)-2-System, IL-6 und granulocyte colony-stimulating factor (G-CSF). Die vorliegende Arbeit diskutiert die Bedeutung dieser Zytokine für die Pathogenese und Pathophysiologie Clozapin-induzierter Nebenwirkungen. Mit großer Wahrscheinlichkeit spielt TNF-α eine wichtige pathogenetische Rolle für das Clozapin-induzierte Fieber und die hämatopoetischen Nebenwirkungen einschließlich der Agranulozytose. Darüber hinaus gibt es Hinweise darauf, dass TNF-α und andere Zytokine auch in endokrin-metabolische (Gewichtszunahme, Induktion einer diabetischen Stoffwechsellage), kardiale (Myokarditis), zentralnervöse (Sedierung) und einige andere, sehr seltene Nebenwirkungen involviert sind. Die Mechanismen, die den immunmodulatorischen Wirkungen von Clozapin zugrunde liegen, sind nicht bekannt, weshalb in diesem Bereich dringender Forschungsbedarf besteht. Von entsprechenden Untersuchungen sind wesentliche Erkenntnisse hinsichtlich der Pathogenese der erwähnten Nebenwirkungen und Impulse für die Entwicklung prophylaktischer und therapeutischer Strategien zu erwarten.

On the Clinical Relevance of Clozapine-Triggered Release of Cytokines and Soluble Cytokine-Receptors:

Cytokines are pivotal mediators of the interaction between immunocompetent cells. Moreover, they mediate the interaction between the immune system and other physiological systems, including the CNS. It has been shown recently that the antipsychotic drug clozapine stimulates in vivo the release of cytokines and soluble cytokine receptors. This holds true for the tumor necrosis factor(TNF)-system, the interleukin(IL)-2-system, IL-6, and granulocyte colony-stimulating factor (G-CSF). The present paper discusses the clinical relevance of these findings for the pathophysiology of clozapine-induced side-effects. It is very probable that TNF-α plays an important role in clozapin-induced fever and in the hematopoetic side effects, including agranulocytosis. Moreover, it is likely that TNF-α and other cytokines are involved in metabolic (weight gain, diabetes), cardiac (myocarditis), CNS (sedation) and other rare side effects. The mechanisms underlying clozapine-induced immunomodulation are unknown. Hence, further studies are very important to enhance our understanding of clozapins's side effects and to develop strategies for prevention and treatment.

Literatur

  • 1 Gross H, Langner E. Das Wirkungsprofil eines chemisch neuartigen Breitbandneuroleptikums der Dibenzodiazepingruppe.  Wiener Medizinische Wochenschrift. 1966;  116 814-816
    PubMedSearch in Google Scholar
  • 2 Angst J, Bente D, Berner P, Heimann H, Helmchen H, Hippius H. Das klinische Wirkungsbild von Clozapin.  Pharmakopsychiatrie und Neuro-Psychopharmakologie. 1971;  4 201-211
    PubMedSearch in Google Scholar
  • 3 Baldessarini R J, Frankenburg F R. Clozapine. A novel antipsychotic agent.  New England Journal of Medicine. 1991;  324 746-754
    PubMedSearch in Google Scholar
  • 4 Meltzer H Y, McGurk S R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.  Schizophrenia Bulletin. 1999;  25 233-255
    PubMedSearch in Google Scholar
  • 5 Pickar D. Prospects for pharmacotherapy of schizophrenia.  Lancet. 1995;  345 557-562
    CrossrefPubMedSearch in Google Scholar
  • 6 Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva I P. Agranulocytosis during treatment with clozapine.  European Journal of clinical Pharmacology. 1977;  11 193-198
    CrossrefPubMedSearch in Google Scholar
  • 7 Pisciotta A V. Agranulocytosis induced by certain phenothiazine derivatives.  Journal of the American Medical Association. 1969;  208 1862-1868
    CrossrefPubMedSearch in Google Scholar
  • 8 Alvir J M, Lieberman J A, Safferman A Z, Schwimmer J L, Schaaf J A. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.  New England Journal of Medicine. 1993;  329 162-167
    CrossrefPubMedSearch in Google Scholar
  • 9 Lambertenghi D G. Blood dyscrasias in clozapine-treated patients in Italy.  Haematologica. 2000;  85 233-237
    PubMedSearch in Google Scholar
  • 10 Gerson S L. G-CSF and the management of clozapine-induced agranulocytosis.  Journal of Clinical Psychiatry. 1994;  55 Suppl B 139-142
    PubMedSearch in Google Scholar
  • 11 Blum A, Mauruschat W. Temperaturanstiege und Bluteiweißveränderungen unter der Therapie mit Neuroleptika - unter besonderer Berücksichtigung des neuartigen Dibenzodiazepin-Derivates Clozapin.  Pharmakopsychiatrie. 1972;  5 155-169
    PubMedSearch in Google Scholar
  • 12 Pollmächer T. Schlaf, Immunsystem und Neuroleptika - ein Beitrag zur experimentellen Psychoneuroimmunologie. München: MMV Verlag 2000
    Search in Google Scholar
  • 13 Dinarello C A. The interleukin-1 family: 10 years of discovery.  FASEB Journal. 1994;  8 1314-1325
    PubMedSearch in Google Scholar
  • 14 Pollmächer T, Hinze-Selch D, Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels.  Journal of Clinical Psychopharmacology. 1996;  16 403-409
    CrossrefPubMedSearch in Google Scholar
  • 15 Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmächer T. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight.  Psychopharmacology (Berl). 2000;  149 163-169
    CrossrefPubMedSearch in Google Scholar
  • 16 Monteleone P, Fabrazzo M, Tortorella A, Maj M. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment.  Psychiatry Research. 1997;  71 11-17
    CrossrefPubMedSearch in Google Scholar
  • 17 Pollmächer T, Hinze-Selch D, Fenzel T, Kraus T, Schuld A, Mullington J. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol.  American Journal of Psychiatry. 1997;  154 1763-1765
    PubMedSearch in Google Scholar
  • 18 Pollmächer T, Fenzel T, Mullington J, Hinze-Selch D. The influence of clozapine treatment on plasma granulocyte colony-stimulating (G-CSF) levels.  Pharmacopsychiatry. 1997;  30 118-121
    PubMedSearch in Google Scholar
  • 19 Pollmächer T, Hinze-Selch D, Mullington J, Holsboer F. Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors.  Archives of General Psychiatry. 1995;  52 877-878
    PubMedSearch in Google Scholar
  • 20 Maes M, Meltzer H Y, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine.  Acta Psychiatrica Scandinavica. 1994;  89 346-351
    PubMedSearch in Google Scholar
  • 21 Maes M, Bosmans E, Kenis G, De Jong R, Smith R S, Meltzer H Y. In vivo immunomodulatory effects of clozapine in schizophrenia.  Schizophrenia Research. 1997;  26 221-225
    CrossrefPubMedSearch in Google Scholar
  • 22 Sperner-Unterweger B, Gaggl S, Fleischhacker W W, Barnas C, Herold M, Geissler D. Effects of clozapine on hematopoiesis and the cytokine system.  Biological Psychiatry. 1993;  34 536-543
    CrossrefPubMedSearch in Google Scholar
  • 23 Hinze-Selch D, Becker E W, Stein G M, Berg P A, Mullington J, Holsboer F, Pollmächer T. Effects of clozapine on in vitro immune parameters - a longitudinal study in clozapine-treated schizophrenic patients.  Neuropsychopharmacology. 1998;  19 114-122
    CrossrefPubMedSearch in Google Scholar
  • 24 Jones-Brando L V, Buthod J L, Holland L E, Yolken R H, Torrey E F. Metabolites of the antipsychotic agent clozapine inhibit the replication of human immunodeficiency virus type 1.  Schizophrenia Research. 1997;  25 63-70
    CrossrefPubMedSearch in Google Scholar
  • 25 Blalock J E. A molecular basis for bidirectional communication between the immune and neuroendocrine systems.  Physiological Reviews. 1989;  69 1-32
    PubMedSearch in Google Scholar
  • 26 Hampson M E. Clozapine-induced thrombocytosis.  British Journal of Psychiatry. 2000;  176 400
    CrossrefPubMedSearch in Google Scholar
  • 27 Assion H J, Kolbinger H M, Rao M L, Laux G. Lymphocytopenia and thrombocytopenia during treatment with risperidone or clozapine.  Pharmacopsychiatry. 1996;  29 227-228
    PubMedSearch in Google Scholar
  • 28 Rudolf J, Grond M, Neveling M, Heiss W D. Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis.  J Neural Transm. 1997;  104 1305-1311
    CrossrefPubMedSearch in Google Scholar
  • 29 Alvir J M, Lieberman J A, Safferman A Z. Do white-cell count spikes predict agranulocytosis in clozapine recipients?.  Psychopharmacol Bull. 1995;  31 311-314
    PubMedSearch in Google Scholar
  • 30 Hummer M, Kurz M, Barnas C, Saria A, Fleischhacker W W. Clozapine-induced transient white blood count disorders.  Journal of Clinical Psychiatry. 1994;  55 429-432
    PubMedSearch in Google Scholar
  • 31 Hummer M, Sperner-Unterweger B, Kemmler G, Falk M, Kurz M, Oberbauer H, Fleischhacker W W. Does eosinophilia predict clozapine induced neutropenia?.  Psychopharmacology (Berl). 1996;  124 201-204
    CrossrefPubMedSearch in Google Scholar
  • 32 van der Poll T, van Deventer S J, Hack C E, Wolbink G J, Aarden L A, Buller H R, ten Cate J W. Effects on leukocytes after injection of tumor necrosis factor into healthy humans.  Blood. 1992;  79 693-698
    PubMedSearch in Google Scholar
  • 33 Steward W P. Granulocyte and granulocyte-macrophage colony-stimulating factors.  Lancet. 1993;  342 153-157
    CrossrefPubMedSearch in Google Scholar
  • 34 Pollmächer T, Korth C, Mullington J, Schreiber W, Sauer J, Vedder H, Galanos C, Holsboer F. Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men.  Blood. 1996;  87 900-905
    PubMedSearch in Google Scholar
  • 35 Williams D P, Pirmohamed M, Naisbitt D J, Uetrecht J P, Park B K. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine.  Molecular Pharmacology. 2000;  58 207-216
    PubMedSearch in Google Scholar
  • 36 Turbay D, Lieberman J, Alper C A, Delgado J C, Corzo D, Yunis J J, Yunis E J. Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups.  Blood. 1997;  89 4167-4174
    PubMedSearch in Google Scholar
  • 37 Schuld A, Kraus T, Hinze-Selch D, Haack M, Pollmächer T. Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia.  Acta Psychiatrica Scandinavica. 2000;  102 153-155
    CrossrefPubMedSearch in Google Scholar
  • 38 Jensen V E, Gotzsche O. Allergic myocarditis in clozapine treatment.  Ugeskr Laeger. 1994;  156 4151-4152
    PubMedSearch in Google Scholar
  • 39 Lilleng P, Morild I, Hope M. Clozapine and myocarditis.  Tidsskr Nor Laegeforen. 1995;  115 3026-3027
    PubMedSearch in Google Scholar
  • 40 Bandelow B, Degner D, Kreusch U, Rüther E. Myocarditis under therapy with clozapine.  Schizophrenia Research. 1995;  17 293-294
    CrossrefPubMedSearch in Google Scholar
  • 41 Khalil N. Peri-/Myokarditis unter Clozapin (Leponex).  Psychiatr Prax. 1997;  24 46
    PubMedSearch in Google Scholar
  • 42 Killian J G, Kerr K, Lawrence C, Celermajer D S. Myocarditis and cardiomyopathy associated with clozapine.  Lancet. 1999;  354 1841-1845
    CrossrefPubMedSearch in Google Scholar
  • 43 Meldrum D R. Tumor necrosis factor in the heart.  American Journal of Physiology. 1998;  274 R577-R595
    PubMedSearch in Google Scholar
  • 44 Feldman A M, Combes A, Wagner D, Kadakomi T, Kubota T, Li Y Y, McTiernan C. The role of tumor necrosis factor in the pathophysiology of heart failure.  J Am Coll Cardiol. 2000;  35 537-544
    CrossrefPubMedSearch in Google Scholar
  • 45 Kellner M, Wiedemann K, Krieg J C, Berg P A. Toxic hepatitis by clozapine treatment.  American Journal of Psychiatry. 1993;  150 985-986
    PubMedSearch in Google Scholar
  • 46 Bauer M. Concurrent agranulocytosis and acute hepatitis resulting from combination of classic neuroleptics and subsequent successful clozapine treatment.  Pharmacopsychiatry. 1995;  28 29-31
    PubMedSearch in Google Scholar
  • 47 Worrall R, Wilson A, Cullen M. Dystonia and drug-induced hepatitis in a patient treated with clozapine.  American Journal of Psychiatry. 1995;  152 647-648
    PubMedSearch in Google Scholar
  • 48 Thatcher G W, Cates M, Bair B. Clozapine-induced toxic hepatitis.  American Journal of Psychiatry. 1995;  152 296-297
    PubMedSearch in Google Scholar
  • 49 Macfarlane B, Davies S, Mannan K, Sarsam R, Pariente D, Dooley J. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity.  Gastroenterology. 1997;  112 1707-1709
    PubMedSearch in Google Scholar
  • 50 Hummer M, Kurz M, Kurzthaler I, Oberbauer H, Miller C, Fleischhacker W W. Hepatotoxicity of clozapine.  Journal of Clinical Psychopharmacology. 1997;  17 314-317
    CrossrefPubMedSearch in Google Scholar
  • 51 Frankenburg F R, Kando J. Eosinophilia, clozapine, and pancreatitis [letter].  Lancet. 1992;  340 251
    PubMedSearch in Google Scholar
  • 52 Bergemann N, Ehrig C, Diebold K, Mundt C, von Einsiedel R. Asymptomatic pancreatitis associated with clozapine.  Pharmacopsychiatry. 1999;  32 78-80
    PubMedSearch in Google Scholar
  • 53 Cerulli T R. Clozapine-associated pancreatitis.  Harvard Review of Psychiatry. 1999;  7 61-63
    CrossrefPubMedSearch in Google Scholar
  • 54 Norman J. The role of cytokines in the pathogenesis of acute pancreatitis.  Am J Surg. 1998;  175 76-83
    PubMedSearch in Google Scholar
  • 55 Robinson D, Fenn H, Yesavage J. Possible association of parotitis with clozapine.  American Journal of Psychiatry. 1995;  152 297-298
    PubMedSearch in Google Scholar
  • 56 Hinze-Selch D, Becker E W, Stein G, Schreiber W, Pollmächer T. Clozapine-induced parotitis - an immunological cause?.  American Journal of Psychiatry. 1996;  153 840
    PubMedSearch in Google Scholar
  • 57 Allison D B, Mentore J L, Heo M, Chandler L P, Cappelleri J C, Infante M C, Weiden P J. Antipsychotic-induced weight gain: a comprehensive research synthesis.  American Journal of Psychiatry. 1999;  156 1686-1696
    PubMedSearch in Google Scholar
  • 58 Brömel T, Blum W F, Ziegler A, Schulz E, Bender M, Fleischhaker C, Remschmidt H, Krieg J C, Hebebrand J. Serum leptin levels increase rapidly after initiation of clozapine therapy.  Molecular Psychiatry. 1998;  3 76-80
    CrossrefPubMedSearch in Google Scholar
  • 59 Auwerx J, Staels B. Leptin.  Lancet. 1998;  351 737-742
    CrossrefPubMedSearch in Google Scholar
  • 60 Kraus T, Haack M, Schuld A, Hinze-Selch D, Kühn M, Uhr M, Pollmächer T. Body weight and leptin plasma levels during treatment with antipsychotic drugs.  American Journal of Psychiatry. 1999;  156 312-314
    PubMedSearch in Google Scholar
  • 61 Hinze-Selch D, Schuld A, Kraus T, Kühn M, Uhr M, Haack M, Pollmächer T. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-α and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology, in press
  • 62 Gainsford T, Alexander W S. A role for leptin in hemopoieses?.  Mol Biotechnol. 1999;  11 149-158
    PubMedSearch in Google Scholar
  • 63 Ahima R S, Bjorbaek C, Osei S, Flier J S. Regulation of neuronal and glial proteins by leptin: implications for brain development.  Endocrinology. 1999;  140 2755-2762
    CrossrefPubMedSearch in Google Scholar
  • 64 Finck B N, Johnson R W. Tumor necrosis factor-alpha regulates secretion of the adipocyte-derived cytokine, leptin.  Microsc Res Tech. 2000;  50 209-215
    CrossrefPubMedSearch in Google Scholar
  • 65 Langhans W, Hrupka B. Interleukins and tumor necrosis factor as inhibitors of food intake.  Neuropeptides. 1999;  33 415-424
    CrossrefPubMedSearch in Google Scholar
  • 66 Argilés J M, López-Soriano J, Busquets S, López-Soriano F J. Journey from cachexia to obesity by TNF.  FASEB Journal. 1997;  11 743-751
    PubMedSearch in Google Scholar
  • 67 Bulló-Bonet M, García-Lorda P, López-Soriano F J, Argilés J M, Salas-Salvadó J. Tumour necrosis factor, a key role in obesity?.  FEBS Letters. 1999;  451 215-219
    CrossrefPubMedSearch in Google Scholar
  • 68 Hauner H, Bender M, Haastert B, Hube F. Plasma concentrations of soluble TNF-alpha receptors in obese subjects.  Int J Obes Relat Metab Disord. 1998;  22 1239-1243
    CrossrefPubMedSearch in Google Scholar
  • 69 Moller D E. Potential Role of TNF-alpha in the Pathogenesis of Insulin Resistance and Type 2 Diabetes.  Trends in Endocrinology & Metabolism. 2000;  11 212-217
    PubMedSearch in Google Scholar
  • 70 Melkersson K I, Hulting A L, Brismar K E. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses.  Journal of Clinical Psychiatry. 1999;  60 783-791
    PubMedSearch in Google Scholar
  • 71 Hägg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications.  Journal of Clinical Psychiatry. 1998;  59 294-299
    PubMedSearch in Google Scholar
  • 72 Henderson D C, Cagliero E, Gray C, Nasrallah R A, Hayden D L, Schoenfeld D A, Goff D C. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.  American Journal of Psychiatry. 2000;  157 975-981
    CrossrefPubMedSearch in Google Scholar
  • 73 Rigalleau V, Gatta B, Bonnaud S, Masson M, Bourgeois M L, Vergnot V, Gin H. Diabetes as a result of atypical anti-psychotic drugs - a report of three cases.  Diabet Med. 2000;  17 484-486
    CrossrefPubMedSearch in Google Scholar
  • 74 Maule S, Giannella R, Lanzio M, Villari V. Diabetic ketoacidosis with clozapine treatment.  Diabetes Nutr Metab. 1999;  12 187-188
    PubMedSearch in Google Scholar
  • 75 Colli A, Cocciolo M, Francobandiera F, Rogantin F, Cattalini N. Diabetic ketoacidosis associated with clozapine treatment.  Diabetes Care. 1999;  22 176-177
    PubMedSearch in Google Scholar
  • 76 Smith H, Kenney-Herbert J, Knowles L. Clozapine-induced diabetic ketoacidosis.  Australian & New Zealand Journal of Psychiatry. 1999;  33 120-121
    PubMedSearch in Google Scholar
  • 77 Ai D, Roper T A, Riley J A. Diabetic ketoacidosis and clozapine.  Postgrad Med J. 1998;  74 493-494
    PubMedSearch in Google Scholar
  • 78 Pierides M. Clozapine monotherapy and ketoacidosis.  British Journal of Psychiatry. 1997;  171 90-91
    PubMedSearch in Google Scholar
  • 79 Peterson G A, Byrd S L. Diabetic ketoacidosis from clozapine and lithium cotreatment.  American Journal of Psychiatry. 1996;  153 737-738
    PubMedSearch in Google Scholar
  • 80 Koval M S, Rames L J, Christie S. Diabetic ketoacidosis associated with clozapine treatment.  American Journal of Psychiatry. 1994;  151 1520-1521
    PubMedSearch in Google Scholar
  • 81 Popli A P, Konicki P E, Jurjus G J, Fuller M A, Jaskiw G E. Clozapine and associated diabetes mellitus.  Journal of Clinical Psychiatry. 1997;  58 108-111
    PubMedSearch in Google Scholar
  • 82 Kluger M J. Fever: role of pyrogens and cryogens.  Physiological Reviews. 1991;  71 93-127
    PubMedSearch in Google Scholar
  • 83 Shoham S, Davenne D, Cady A B, Dinarello C A, Krueger J M. Recombinant tumor necrosis factor and interleukin 1 enhance slow-wave sleep.  American Journal of Physiology. 1987;  253 R142-R149
    PubMedSearch in Google Scholar
  • 84 Pollmächer T, Schuld A, Kraus T, Haack M, Hinze-Selch D, Mullington J. Schlaf und Schläfrigkeit im Rahmen von Infektionen und im Rahmen experimenteller Immunmodulation beim Menschen.  Somnologie. 2000;  4 68-78
    CrossrefPubMedSearch in Google Scholar
  • 85 Pollmächer T, Schuld A, Kraus T, Haack M, Hinze-Selch D, Mullington J. Experimental immunomodulation, sleep and sleepiness in humans. Annals of the New York Academy of Sciences, in press
  • 86 Mullington J, Korth C, Hermann D M, Orth A, Galanos C, Holsboer F, Pollmächer T. Dose-dependent effects of endotoxin on human sleep.  American Journal of Physiology Regulatory, Integrative and Comparative Physiology. 2000;  278 R947-R955
    PubMedSearch in Google Scholar
  • 87 Wetter T C, Lauer C J, Gillich G, Pollmächer T. The electroencephalographic sleep pattern in schizophrenic patients treated with clozapine or classical antipsychotic drugs.  Journal of Psychiatric Research. 1996;  30 411-419
    PubMedSearch in Google Scholar
  • 88 Hinze-Selch D, Mullington J, Orth A, Lauer C J, Pollmächer T. Effects of clozapine on sleep: a longitudinal study.  Biological Psychiatry. 1997;  42 260-266
    CrossrefPubMedSearch in Google Scholar
  • 89 Hinze-Selch D, Mullington J, Pollmächer T. Sleep during clozapine-induced fever in a schizophrenic patient.  Biological Psychiatry. 1995;  38 690-693
    CrossrefPubMedSearch in Google Scholar
  • 90 Pollmächer T, Haack M, Schuld A, Kraus T, Hinze-Selch D. Effects of antipsychotic drugs on cytokine networks.  Journal of Psychiatric Research. 2000;  34 369-382
    CrossrefPubMedSearch in Google Scholar
  • 91 Hopkins S J, Rothwell N J. Cytokines and the nervous system I: expression and recognition.  Trends in Neurosciences. 1995;  18 83-88
    CrossrefPubMedSearch in Google Scholar
  • 92 Tracey K J, Cerami A. Tumor necrosis factor: an updated review of its biology.  Crit Care Med. 1993;  21 S415-S422
    PubMedSearch in Google Scholar

Priv.-Doz. Dr. med. Thomas Pollmächer

Max Planck Institut für Psychiatrie

Kraepelinstrasse 10

80804 München

Email: E-mail: topo@mpipsykl.mpg.de